UK Study Finds Pfizer/Bristol Myers Clotting Drug Does Not Help COVID-19 Patients - Bristol-Myers Squibb (NYSE:BMY)

According to a U.K. trial, Eliquis (apixaban), widely prescribed for COVID-19, did not help patients recovering from moderate and severe COVID.
The drug used after discharge from the hospital does not lessen the chances for COVID-19 patients of readmission or improve survival.
The results were shared with the Financial Times.
Eliquis is indicated to reduce the risk of stroke and blood clots in people with nonvalvular atrial fibrillation, a type of irregular heartbeat.
Related: National Institutes of Health's Long COVID Initiative To Assess Pfizer's Antiviral Pill As Potential Treatment.
Apixaban is jointly commercialized by Pfizer Inc PFE and Bristol Myers Squibb Co BMY.
Researchers also found that a small number of cases caused serious harm.
Around 29.1% of people given the drug ended up back in the hospital or died, compared with 30.8% receiving standard care.
The 402-subject study showed no benefit from Apixaban regarding the number of days patients remained alive and out of the hospital 60 days after their initial discharge.
The study will continue to test another drug called Atorvastatin, a widely used lipid-lowering drug, or "statin," that acts on other mechanisms of disease that are thought to be important in COVID.
Photo Via Company